FranΓ§aisπ See the interactive version (live chart) β
| Metric | Value | What it means |
|---|---|---|
| P/E (price / earnings) | 19.5 | The higher, the more growth the market expects. |
| Forward P/E | 13.6 | On next year's expected earnings. Lower than current P/E = rising earnings. |
| PEG (P/E Γ· growth) | 1.29 | Below 1 = cheap given growth; above 2 = expensive. |
| Net margin | 17% | Share of revenue that ends up as profit. |
| Revenue growth | 8% | Pace of revenue growth. |
| Price-to-book | 2.7 | Price relative to book value. |
| Market cap | $67.6 B | Total market value of the company. |
| Dividend yield | β | No dividend currently. |
| Year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2022 | $12.7 B | $642 M | 5% |
| 2023 | $14.2 B | $1.6 B | 11% |
| 2024 | $16.7 B | $1.9 B | 11% |
| 2025 | $20.1 B | $2.9 B | 14% |
π Open the interactive Boston Scientific page (charts, live news) β
Boston Scientific has a P/E of 19.5 (forward P/E 13.6) and a PEG of 1.29. A PEG below 1 is rather cheap given growth, above 2 is expensive. Verdict: reasonable valuation.
Boston Scientific's net margin is about 17% β the share of revenue that ends up as net profit.
Latest known revenue: $20.1 B for net income of $2.9 B. The year-by-year breakdown is in the income statement above.
Boston Scientific (BSX) has a market cap of about $67.6 B.
No, Boston Scientific does not currently pay a dividend (it reinvests earnings).
JPI Invest aggregates analyst recommendations across the entire S&P 500 (plus the S&P MidCap 400), replays them against real prices and measures who predicts best β on results, not reputation. Instead of taking a price target at face value, you see each analyst's track record on each stock.
Explore JPI Invest for free β How it works: the method β
β οΈ Educational information, not investment advice. Data: Yahoo Finance, recomputed by JPI Invest. A stock can be Β« cheap Β» for a bad reason.